Introduction
Endothelial nitric oxide synthase (eNOS) is a crucial enzyme for vascular physiology; its reduced activity during ageing is associated with increased susceptibility to cardio-and cerebro-vascular diseases. [1] [2] [3] [4] Moreover, in mice lacking eNOS, caloric restriction does not exert its positive effects in delaying ageing and increasing life span. 5 Long-living individuals (LLIs) have a favorable genetic profile characterized by an enrichment of alleles associated with the protection from ageing and cardiovascular disease. 6, 7 We have recently shown for three different populations that LLIs are enriched for rs2070325 (I229V), the minor allele of bactericidal/permeability-increasing fold-containing family B member 4 (BPIFB4). 8 rs2070325 was one of four single-nucleotide polymorphisms on BPIFB4 that variously combined to generate BPIFB4 isoforms, such as the wild type (WT) protein and a longevity-associated variant (LAV). Of note, the LAV-BPIFB4 was associated with potentiated eNOS activity in cells, an effect correlated with increased binding of BPIFB4 to 14-3-3-through an atypical-binding site for the proteinand increased phosphorylation of BPIFB4 at serine 75-a site recognized by protein kinase R-like endoplasmic reticulum kinase (PERK).
Heat shock protein 90 (HSP90) was also recruited to the LAV-14-3-3 complex as part of the eNOS activation machinery. Indeed, HSP90 coimmunoprecipitated with BPIFB4, and a specific HSP90 inhibitor blocked the potentiation of endothelial function and eNOS activation exerted by the LAV. 8 Despite these findings, further characterization is needed to define how LAV-BPIFB4 transduces upstream signals to eNOS. 9 On this point, we already reported that LAV-BPIFB4 enhanced acetylcholine (ACh)-evoked vasorelaxation. ACh-induced eNOS phosphorylation and activity requires capacitive Ca 2þ influx. 10 This function is mediated by protein kinase C alpha (PKCa), which stimulates nitric oxide (NO) production in endothelial cells and plays a role in regulating blood flow in vivo. 11 In the present study, we demonstrate that PKCa is part of the signalling pathway activated by LAV-BPIFB4 to potentiate vascular function. In particular, we show that LAV-BPIFB4 activates eNOSdependent endothelial function through Ca 2þ -mediated potentiation of PKCa. Moreover, when PKCa and/or eNOS is inactivated-e.g. by exposing cells to Ca 2þ -free media or knocking out eNOS-LAV-BPIFB4
can still enhance vasorelaxation through an endothelium-derived hyperpolarizing factor (EDHF)-mediated pathway.
Methods
All experiments involving animals conformed to the guidelines for the Care and Use of Laboratory Animals published with Directive 2010/63/ EU of the European Parliament and were approved by the review board of IRCCS INM Neuromed (ref. number 1070/2015 PR). C57BL/6 mice were bred in our animal facility. eNOS knockout (KO) mice were obtained from the Jackson Laboratory. All effort was made to minimize the number of animals used and their suffering.
Ex vivo transfection of mouse vessels and evaluation of vascular reactivity
Mice were sacrificed by intraperitoneal injection of ketamine/xylazine (respectively, 150 and 20 mg/kg BW), and second-order branches of the mesenteric arterial tree were surgically removed and mounted on a pressure myograph for experiments. 8 Endothelium-dependent relaxation was assessed by measuring the dilatory responses of mesenteric arteries to cumulative concentrations of ACh (from 10 -9 to 10 -5 M) in vessels precontracted with U46619 at a dose necessary to obtain a similar level of pre-contraction in each ring (80% of initial KCl-evoked contraction). 12 Values are reported as the percentage of lumen diameter change after drug administration. Responses were tested before and after transfection. ACh-evoked vasorelaxation was also tested in the presence of the PKCa inhibitor Gö6976 (0.5 lM) or the AKT inhibitor IL6-hydroxymethyl-chiro-inositol-2-(R)-2-O-methyl-3-O-octadecyl-snglycerocarbonate (10 mM) (no. 124005, Calbiochem). In some experiments, the endothelium was mechanically removed by inserting a tungsten wire into the lumen of the vessel and rotating it back and forth before mounting the vessel on the pressure myograph. Caution was taken to avoid endothelial damage.
Another experimental series was performed on vessels transfected in presence of Ca 2þ and then studied in the absence of external Ca 2þ , Lysates were cleared at 13 000 rpm for 20 min at 4 C, and 700 lg protein incubated overnight with 2 lg of mouse anti-GFP (Invitrogen), mouse anti-14-3-3 (Abcam), or mouse anti-IgG (Millipore) for the control. The antibody-antigen complexes were precipitated with Glinked Sepharose protein (GE Healthcare) for 4 h at 4 C and the beads washed three times with lysis buffer. The denatured co-immunoprecipitation products were resolved with SDS-PAGE, electro-blotted onto PVDF membranes, and hybridized with 1:1000 rabbit anti-14-3-3 (Abcam).
Western blotting
Each sample was a pool of mesenteric arteries (length, 2mm; diameter, 250 mm) excised from four mice. HUVECs infected with lentiviral particles encoding WT-BPIFB4, LAV-BPIFB4, or GFP ('empty' vector) were starved in serum-and growth factor-free EGM-2 for 4 h and then stimulated with 100 mM ACh for 10 min. Protein extracts were separated on 8-10% SDS-PAGE at 100 V for 1 h or on 4-12% SDS-PAGE at 100 V for 2 h and then transferred to a nitrocellulose or PVDF membrane as previously described in. 8 Western blots were analysed using ImageJ software (Wayne Rasband, National Institutes of Health, USA) to determine optical density (OD) of the bands. The OD readings of phosphorylated proteins are expressed as a ratio relative to total protein or to beta-actin. All other protein expressions are normalized to account for variations in loading. 
Ca 2þ -transient recordings

Immunofluorescence and confocal microscopy
HUVECs infected with lentiviral particles encoding WT-BPIFB4, LAV-BPIFB4, or GFP (empty vector) were fixed in 4% paraformaldehyde in PBS for 20 min, washed twice in 50 mM NH 4 Cl in PBS, and permeabilized for 5 min in 0.2% Triton X-100 in PBS. Fixed cells were treated as described elsewhere. 15 Immunofluorescence analysis was performed on an inverted, motorized microscope (Axio Observer Z.1) equipped with a 63X/1. Triple staining fluorescence images were acquired separately using ZEN 2012 software in the blue (Hoechst 33258), green (EGFP), and red (Alexa Fluor 594) channels at a resolution of 1024 Â 1024 pixels, with the confocal pinhole set to one Airy unit, and then saved in TIFF format.
Statistical analyses
Vessel reactivity is given as mean ± S.E.M. and analysed by two-way ANOVA. Densitometry data were analysed with one-way ANOVA followed by Bonferroni post hoc analysis, as appropriate, using dedicated software (GraphPad Prism, v5.0).
Results
LAV-BPIFB4 activates PKCa
We previously reported that LAV-BPIFB4 enhances NO-mediated vasorelaxation evoked by ACh. 8 ACh-evoked vasodilation of isolated mesenteric vessels has been reported to require intact PKCa activity. 10 Here, found that PKCa was more phosphorylated at threonine 497-an activation site of the enzyme-in LAV-BPIFB4-overexpressing vessels than in those expressing the WT protein or only GFP ( Figure 1A) . Expression of LAV-BPIFB4 protein was detected through FACS analysis in 79 ± 4% CD31 þ endothelial cells (data not shown). To confirm that the mechanisms recruited by LAV-BPIFB4 take place in endothelial cells, we performed Western blotting on HUVECs infected with lentiviral vectors encoding GFP (empty), WT-BPIFB4, or LAV-BPIFB4. Also in this experimental setting, overexpression of LAV-BPIFB4 was associated with activation of PKCa and eNOS ( Figure 1B) .
To better characterize the role of the endothelial and smooth muscle layers, we performed experiments on endothelium-denuded vessels: the loss of endothelium was confirmed by the absence of eNOS upon Western blotting ( Figure 1C) and by the absence of ACh-evoked vasorelaxation in functional studies (data not shown). Overexpression of LAV-BPIFB4 upregulated the phosphorylation of eNOS by about 2.5-fold and evoked the activation of PKCa regardless of the presence or not of endothelium ( Figure 1C) .
Of note, treatment with the PKCa inhibitor Gö6976 significantly blunted ACh-evoked vasorelaxation in control vessels ( Figure 2A ) and abolished both endothelial vasorelaxation and enhanced eNOS phosphorylation in LAV-BPIFB4-expressing vessels ( Figure 2B and C) . Based on these results, we can assert that PKCa is recruited by LAV-BPIFB4 to modulate eNOS and vascular tone.
BPIFB4 isoforms modulate Ca 2þ influx and translocation of PKCa to membrane
Based on the modulatory action of BPIFB4 on PKCa activity and vascular function-well-known Ca 2þ -dependent processes 10 we investigated how agonist-induced Ca 2þ mobilization was influenced by the expression of the BPIFB4 isoforms in HUVECs. ATP was used to elicit Ca 2þ transients ( Figure 3A) , so avoiding interaction of ACh with the nicotinic receptors present on the HUVECs. 16 Overexpression of the LAV-BPIFB4 isoform determined clear increases in the number of responsive cells ( Figure 3B ) and the mean amplitude of Ca 2þ transient upon stimulation ( Figure 3C) . Thus, the LAV isoform clearly facilitates agonist-induced Ca 2þ mobilization. Moreover, overexpression of LAV-BPIFB4 was associated with increased localization of PKCa to the plasma membrane ( Figure 3D ), a hallmark of its activation. 17, 18 The percentages of cells with membrane-localized PKCa in each setting were: empty, 6.5%; WT-BPIFB4, 10%; LAV-BPIFB4, 60%. 19, 20 and connexin-43 (Cx43) plays a prominent role in this mechanism. 21 We found increased expression of Cx43 in vessels overexpressing LAV-BPIFB4 ( Figure 3E ). Based on this finding, we speculate that Cx43 could be involved in the effects of LAV-BPIFB4 on Ca 2þ mobilization.
In previous work, we reported that mononuclear cells (MNCs) from homozygous rs2070325 carriers (which express LAV-BPIFB4) have significantly upregulated eNOS activity vs. those from heterozygous and WT carriers. 8 To exclude that this mechanism was responsible for the above findings, we assessed recruitment of MNCs to vessels. Evaluation Figure 1 Effect of LAV-BPIFB4 on PKCa/eNOS signalling. Representative Western blots of (A) ex vivo C57BL/6 mouse mesenteric arteries, (B) HUVECs, and (C) vessels with (Eþ) or without (E-) endothelium, transfected with an empty vector (E) or vectors for the expression of WT BPIFB4 or LAV-BPIFB4. Graphs on the right show quantification of p-eNOS (S1177), p-PKCa (T497), p-BPIFB4 (S75), and BPIFB4. Values are means ± S.E.M., n = 6 experiments for A; n = 3 experiments for B and C. 23 but not in those overexpressing LAV-BPIFB4 ( Figure 3E ).
LAV-BPIFB4 fails to activate PKCa and eNOS in the absence of external Ca 2þ
ACh-evoked eNOS phosphorylation requires influx of Ca 2þ . 10 To clarify the role of Ca 2þ in the vascular action of LAV-BPIFB4, we conducted vascular reactivity studies on mesenteric arteries in the absence of external Ca 2þ . In the Ca 2þ -free condition, LAV-BPIFB4 was hypo-phosphorylated and not able to enhance PKCa and eNOS phosphorylation ( Figure 4A ). However, endothelial vasorelaxation was still enhanced ( Figure 4B ). In addition to NO, endothelium generates other mediators involved in the regulation of vascular tone, among which is EDHF. 24 Thus, we inhibited EDHF release using APA-which blocks ATP-type Ca þ2 -activated K þ channels and SK Ca -plus CTx-which blocks voltage-gated Ca 2þ -activated K þ channels (Kv1.3) and BK Ca channels. We found that when EDHF release was inhibited in the absence of external Ca 2þ , LAV-BPIFB4 failed to enhance endothelial vasorelaxation ( Figure 4C ). Taken together, these findings demonstrate that in the presence of external Ca 2þ , LAV-BPIFB4 enhances endothelial function via a PKCa-eNOSmediated mechanism, whereas in the absence of Ca 2þ , LAV-BPIFB4 functions via an EDHF-mediated pathway. This was supported by experiments performed on eNOS -/-vessels: indeed, LAV-BPIFB4 was still able to enhance endothelial vasorelaxation in the absence of eNOS, but this effect was blunted in the presence of EDHF inhibition ( Figure 4D ).
PKCa is involved in a feed-forward mechanism on BPIFB4
We have previously reported that phosphorylation of serine 75 in BPIFB4 by PERK which is enhanced in the presence of the LAV isoform, induces binding to 14-3-3 and activation of eNOS. 8 Detailed amino acid sequencing analysis revealed that serine 75 is also within a potential phosphorylation substrate motif for PKCa (amino acids 73-75: SXR/SIR). Thus, we hypothesized that PKCa contributes to eNOS activation also through its phosphorylation of BPIFB4. We first evaluated signalling in mesenteric vessels in which LAV-BPIFB4 could not be phosphorylated by PERK (namely by overexpressing a protein mutated in the PERK-phosphorylation site-LAV-BPIFB4 mutPERK -or by overexpressing the LAV isoform in the presence of the PERK inhibitor GSK2606414) or bound to 14-3-3 (by overexpressing a protein mutated in the 14-3-3-binding site-LAV-BPIFB4 mut14-3-3
). In these setting, BPIFB4 was hypo-phosphorylated and eNOS was inactive, but PKCa Figure 5A ). When the phosphorylation of PKCa was inhibited, LAV-BPIFB4 did not co-immunoprecipitate with 14-3-3 ( Figure 5B) . Indeed, as shown earlier, inhibition of PKCa significantly reduced phosphorylation of LAV-BPIFB4 at serine 75 and phosphorylation of eNOS ( Figure 2C ), indicating that PKCa is needed for the activation of LAV-BPIFB4 and eNOS. Because Akt signalling is one on the most important pathways modulating eNOS function, 25, 26 we performed experiments in the presence of Akt inhibition. In this experimental condition, vessels transfected with empty vector had significantly impaired ACh-evoked vasorelaxation, whereas those overexpressing LAV-BPIFB4 were still able to enhance ACh vasorelaxation ( Figure 5C) . These results clearly demonstrate that the vascular effects mediated by LAV-BPIFB4 are independent of Akt signalling.
Discussion
The main finding of this study is that the enhanced ability of the LAV isoform of BPIFB4 to stimulate NO production in the endothelium is due to activation of PKCa signalling. Indeed, the overexpression of LAV-BPIFB4 in HUVECs augmented Ca 2þ mobilization, increasing translocation of PKCa to the plasma membrane, a step necessary for the activation of the kinase. 17 In the absence of external Ca 2þ , the ability of LAV-BPIFB4
to enhance both PKCa and eNOS phosphorylation was abolished. We demonstrated previously that phosphorylation of BPIFB4 at serine 75 by PERK and the binding to 14-3-3 protein are fundamental for activation of eNOS and endothelial function. 8 So, to further clarify the mechanisms elicited by the LAV isoform, we investigated potential players, focusing our attention on PKCa, a major PKC family member expressed in endothelial cells and involved in regulating eNOS ; ***P < 0.001 vs. or LAV-BPIFB4 plus GSK2606414. (B) Co-immunoprecipitation of BPIFB4 and 14-3-3 in HEK293T cells overexpressing LAV-BPIFB4 tagged with GFP protein and treated with the PKCa inhibitor Gö6976. Immunoprecipitation was performed with anti-GFP (directed toward LAV-BPIFB4-GFP), anti-14-3-3, and anti-IgG (as negative control) antibodies followed by immunoblotting with anti-14-3-3 (n = 2 independent experiments). (C) Dose-response curves for ACh of ex vivo C57BL/6 mouse mesenteric arteries transfected with empty vector (E) or with LAV-BPIFB4 in the presence (þ) or absence of an Akt inhibitor. Values are means ± S.E.M., n = 6 experiments. Statistics was performed using two-way ANOVA; *P < 0.05. 11, 27 We found that inhibition of PKCa impeded the enhancing effects of LAV-BPIFB4 on eNOS and endothelial function, positioning this kinase between BPIFB4 and eNOS. Of note, mutation of LAV-BPIFB4 at its PERK-phosphorylated site or at its 14-3-3-binding site blunted eNOS activation but did not interfere with the ability to activate PKCa. These findings indicate that the activation of PKCa is independent of Ser75 phosphorylation and binding to 14-3-3.
We also found that serine 75 is within a PKC phosphorylation motif (amino acids 73-75: SXR/SIR), 28 indicating that the kinase works also upstream of BPIFB4. Indeed, when we inhibited PKCa, the site serine 75 became hypo-phosphorylated and BPIFB4 did not co-immunoprecipitate with 14-3-3.
All these findings suggest a mechanism whereby the stimulation of Ca 2þ influx by LAV-BPIFB4 leads to the activation PKCa, which in turn increases phosphorylation of BPIFB4 at serine 75; this hyperphosphorylation results in enhanced binding of LAV-BPIFB4 to 14-3-3 and HSP90, 8 allowing eNOS to binding with the complex and become phosphorylated by PKCa ( Figure 6 ). In addition, careful analysis of our data revealed that in the absence of external Ca 2þ , LAV-BPIFB4 still enhanced endothelial vasorelaxation despite blunted phosphorylation of PKCa and eNOS. We found that this effect was dependent upon the recruitment of EDHF, which is known can substitute for NO in settings where eNOS is dysfunctional. 29, 30 To definitively clarify the concept that LAV-BPIFB4 is able to recruit alternative mechanisms protecting endothelial function in the absence of eNOS, we performed experiments on vessels from eNOS deficient mice. Also in this experimental setting, the expression of LAV-BPIFB4 was associated with enhanced endothelial vasorelaxation. More studies are needed to clarify the mechanism through which LAV-BPIFB4 mediates EDHF release. Finally, our study defines the effects of LAV-BPIFB4 on the modulation of eNOS function in endothelial cells; we cannot exclude a contribution by smooth muscle cells in eNOS activation. Further work will be necessary to study this aspect of vasorelaxation.
Conclusions
The LAV of BPIFB4 has tremendous potential for exploitation as an important tool for the treatment of ageing-related diseases because of its effect on NO metabolism. Moreover, the effect of LAV-BPIFB4 on EDHF release opens up new scenarios for enhancing endothelial function via therapeutic targets other than eNOS.
